Variables | HR | 95% CI | p-value |
---|---|---|---|
Age (continuous) | 1.071 | 1.024–1.121 | 0.003 |
KPS (continuous) | 0.992 | 0.965–1.020 | 0.571 |
Gender (male vs. female) | 0.588 | 0.277–1.246 | 0.166 |
Charlson comorbidity score 0 vs. ≥ 1 | 0.889 | 0.390–2.025 | 0.779 |
No involvement of DBS vs. involvement of DBS | 0.756 | 0.386–1.479 | 0.413 |
Refractory vs. relapse | 2.152 | 0.909–5.094 | 0.081 |
Asymptomatic vs. symptomatic | 0.426 | 0.189–0.960 | 0.040 |
Time in remission < vs. ≥ 12 months | 0.773 | 0.313–1.906 | 0.576 |
Any other treatment vs. WBRT/focal radiotherapy | 2.239 | 0.450–11.139 | 0.325 |
Any other treatment vs. HD-MTX-based therapy | 3.720 | 0.548–25.275 | 0.179 |
Any other treatment vs. TMZ monotherapy/TMZ + rituximab | 1.269 | 0.253–6.372 | 0.772 |
Best supportive care vs. any salvage treatment | 6.018 | 0.968–37.406 | 0.054 |